Charles L Sentman Selected Research

Ly49G2 receptor

5/2008

Ly49G2 receptor blockade reduces tumor burden in a leukemia model but not in a solid tumor model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Charles L Sentman Research Topics

Disease

47	Neoplasms (Cancer) 01/2022 - 09/2005
7	Ovarian Neoplasms (Ovarian Cancer) 06/2015 - 05/2007
5	Lymphoma (Lymphomas) 06/2015 - 11/2007
3	Bites and Stings (Sting) 01/2017 - 03/2015
3	Melanoma (Melanoma, Malignant) 06/2015 - 08/2007
3	Leukemia 04/2015 - 01/2006
2	Multiple Myeloma 01/2019 - 10/2008
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2019 - 01/2006
2	Hematologic Neoplasms (Hematological Malignancy) 01/2019 - 04/2015
2	Cytokine Release Syndrome 12/2016 - 01/2016
2	Infections 01/2013 - 11/2009
1	Weight Loss (Weight Reduction) 01/2020
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2019
1	Glioblastoma (Glioblastoma Multiforme) 01/2018
1	Glioma (Gliomas) 01/2018
1	Brain Neoplasms (Brain Tumor) 01/2018
1	Autoimmune Diseases (Autoimmune Disease) 01/2016
1	Inflammation (Inflammations) 01/2016
1	Neuroblastoma 04/2015
1	Ewing Sarcoma (Sarcoma, Ewing) 04/2015
1	Diarrhea 12/2010
1	Hypoxia (Hypoxemia) 05/2008
1	T-Cell Lymphoma (Lymphoma, T Cell) 11/2007
1	Neoplasm Metastasis (Metastasis) 08/2007
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2006
1	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2006

Drug/Important Bio-Agent (IBA)

24	LigandsIBA 01/2022 - 09/2005
17	CytokinesIBA 01/2022 - 09/2005
12	Chimeric Antigen ReceptorsIBA 01/2022 - 04/2013
10	NK Cell Lectin-Like Receptor Subfamily KIBA 11/2015 - 05/2007
6	Natural Killer Cell ReceptorsIBA 01/2022 - 01/2006
6	PerforinIBA 06/2015 - 08/2007
5	AntigensIBA 01/2022 - 04/2013
4	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2011
3	Interleukin-2 (IL2)IBA 01/2022 - 12/2010
3	micaIBA 10/2020 - 06/2006
3	Neoplasm Antigens (Tumor Antigens)IBA 05/2018 - 09/2005
3	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 06/2012 - 08/2009
2	Single-Chain AntibodiesIBA 03/2015 - 03/2011
2	ChemokinesIBA 06/2006 - 09/2005
1	Interleukin-33IBA 01/2022
1	Antigen Receptors (Antigen Receptor)IBA 01/2019
1	EpitopesIBA 10/2017
1	Biological ProductsIBA 01/2016
1	Cell Surface ReceptorsIBA 01/2016
1	Protein Isoforms (Isoforms)IBA 11/2015
1	Messenger RNA (mRNA)IBA 11/2015
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 11/2015
1	Activating Transcription Factor 4IBA 11/2015
1	NectinsIBA 04/2015
1	PolymersIBA 01/2015
1	Angiogenesis InhibitorsIBA 03/2013
1	Natural Cytotoxicity Triggering Receptor 3IBA 09/2012
1	Clodronic Acid (Clodronate)IBA 06/2012
1	Liposomes (Liposome)IBA 06/2012
1	Nitric Oxide Synthase (NO Synthase)IBA 06/2012
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 12/2010
1	Conditioned Culture MediaIBA 11/2009
1	Interleukin-12 (IL 12)IBA 11/2009
1	Interleukin-15 (Interleukin 15)IBA 11/2009
1	PolyethyleneimineIBA 08/2009
1	Therapeutic UsesIBA 08/2009
1	Small Interfering RNA (siRNA)IBA 08/2009
1	VaccinesIBA 09/2008
1	cadherin 5IBA 09/2008
1	Ly49G2 receptorIBA 05/2008
1	Complement System Proteins (Complement)IBA 01/2008
1	Interferon-gamma (Interferon, gamma)IBA 08/2007
1	Carrier Proteins (Binding Protein)IBA 05/2007
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 05/2007
1	Staphylococcal Protein A (Protein A)IBA 05/2007
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2006

Therapy/Procedure

14	Immunotherapy 01/2022 - 09/2005
13	Therapeutics 01/2022 - 01/2006
2	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2018 - 03/2014
2	Drug Therapy (Chemotherapy) 09/2008 - 01/2008
1	Radiotherapy 01/2018
1	Aftercare (After-Treatment) 08/2009
1	Intravenous Injections 11/2007
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2006